ITMI20001984A0 - Uso dell'arginina nella preparazione di un medicamento per la preparazione e trattamento degli effetti collaterali associati alla somministr - Google Patents

Uso dell'arginina nella preparazione di un medicamento per la preparazione e trattamento degli effetti collaterali associati alla somministr

Info

Publication number
ITMI20001984A0
ITMI20001984A0 IT2000MI001984A ITMI20001984A ITMI20001984A0 IT MI20001984 A0 ITMI20001984 A0 IT MI20001984A0 IT 2000MI001984 A IT2000MI001984 A IT 2000MI001984A IT MI20001984 A ITMI20001984 A IT MI20001984A IT MI20001984 A0 ITMI20001984 A0 IT MI20001984A0
Authority
IT
Italy
Prior art keywords
preparation
arginine
administration
treatment
side effects
Prior art date
Application number
IT2000MI001984A
Other languages
English (en)
Inventor
Paolo Colombo
Lorena Muggetti
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of ITMI20001984A0 publication Critical patent/ITMI20001984A0/it
Priority to IT2000MI001984A priority Critical patent/IT1318689B1/it
Priority to CA002421920A priority patent/CA2421920A1/en
Priority to KR10-2003-7003557A priority patent/KR20030045066A/ko
Priority to US10/363,998 priority patent/US20040014693A1/en
Priority to PCT/EP2001/010398 priority patent/WO2002022134A1/en
Priority to BR0113844-8A priority patent/BR0113844A/pt
Priority to EP01983475A priority patent/EP1318817A1/en
Priority to NZ524677A priority patent/NZ524677A/en
Priority to CNA018165168A priority patent/CN1466458A/zh
Priority to SK456-2003A priority patent/SK4562003A3/sk
Priority to CZ2003957A priority patent/CZ2003957A3/cs
Priority to EEP200300096A priority patent/EE200300096A/xx
Priority to JP2002526384A priority patent/JP2004508406A/ja
Priority to IL15475401A priority patent/IL154754A0/xx
Priority to EA200300368A priority patent/EA200300368A1/ru
Priority to MXPA03002114A priority patent/MXPA03002114A/es
Priority to HU0301026A priority patent/HUP0301026A2/hu
Priority to PL01361844A priority patent/PL361844A1/xx
Priority to AU2002214974A priority patent/AU2002214974A1/en
Priority to ARP010104268A priority patent/AR030635A1/es
Priority to PE2001000911A priority patent/PE20020432A1/es
Publication of ITMI20001984A1 publication Critical patent/ITMI20001984A1/it
Priority to NO20031115A priority patent/NO20031115L/no
Priority to ZA200302866A priority patent/ZA200302866B/en
Application granted granted Critical
Publication of IT1318689B1 publication Critical patent/IT1318689B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT2000MI001984A 2000-09-12 2000-09-12 Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla IT1318689B1 (it)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IT2000MI001984A IT1318689B1 (it) 2000-09-12 2000-09-12 Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla
JP2002526384A JP2004508406A (ja) 2000-09-12 2001-09-07 薬剤の静脈内投与に伴う副作用を予防および治療するための薬物の調製におけるアルギニンの使用
EA200300368A EA200300368A1 (ru) 2000-09-12 2001-09-07 Применение аргинина при получении лекарственного средства для профилактики и лечения побочных эффектов, связанных с внутривенным введением фармацевтических препаратов
US10/363,998 US20040014693A1 (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
PCT/EP2001/010398 WO2002022134A1 (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
BR0113844-8A BR0113844A (pt) 2000-09-12 2001-09-07 Uso de arginina na preparação de um medicamento papa a prevenção e tratamento dos efeitos colaterais associados a administração intravenosa de fármacos
EP01983475A EP1318817A1 (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
NZ524677A NZ524677A (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the extravasation of drugs administered by intravenous routes
CNA018165168A CN1466458A (zh) 2000-09-12 2001-09-07 精氨酸在制备用于预防和治疗与静脉内施用药物相关的副作用的药物中的用途
SK456-2003A SK4562003A3 (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
CZ2003957A CZ2003957A3 (cs) 2000-09-12 2001-09-07 Použití argininu při přípravě léků pro prevenci a léčení vedlejších účinků spojených s itravenózním podáním farmaceutických preparátů
EEP200300096A EE200300096A (et) 2000-09-12 2001-09-07 Arginiini ja selle farmatseutiliselt vastuvõetavate soolade kasutamine, antineoplastilist toimeainet ja arginiini sisaldava intravenoosselt manustatava preparaadi kasutamine, toode või komplekt kasutamiseks vähiravis ja preparaat intravenoosseks manu
CA002421920A CA2421920A1 (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
IL15475401A IL154754A0 (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
KR10-2003-7003557A KR20030045066A (ko) 2000-09-12 2001-09-07 약제의 정맥내 투여와 관련된 부작용의 예방 및 치료용약물의 제조에 있어서의 아르기닌의 용도
MXPA03002114A MXPA03002114A (es) 2000-09-12 2001-09-07 Uso de arginina en la preparacion de un medicamento para la prevencion y tratamiento de los efectos secundarios asociados con la administracion intravenosa de productos farmaceuticos.
HU0301026A HUP0301026A2 (hu) 2000-09-12 2001-09-07 Arginin alkalmazása gyógyszer előállításában a gyógyszerek intravénás beadásával társuló mellékhatások megelőzésére és kezelésére
PL01361844A PL361844A1 (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
AU2002214974A AU2002214974A1 (en) 2000-09-12 2001-09-07 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
ARP010104268A AR030635A1 (es) 2000-09-12 2001-09-10 Uso de arginina en la preparacion de un medicamento para la prevencion y el tratamiento de los efectos colaterales asociados con la administracion endovenosa de productos farmaceuticos
PE2001000911A PE20020432A1 (es) 2000-09-12 2001-09-11 El uso de la arginina en la preparacion de un medicamento para la prevencion y el tratamiento de los efectos secundarios asociados a la administracion intravenosa de productos farmaceuticos
NO20031115A NO20031115L (no) 2000-09-12 2003-03-11 Anvendelse av arginin ved fremstilling av et medikament för forebyggelse ogbehandling av bivirkninger forbundet med intravenösadministrering av legemidler
ZA200302866A ZA200302866B (en) 2000-09-12 2003-04-11 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001984A IT1318689B1 (it) 2000-09-12 2000-09-12 Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla

Publications (3)

Publication Number Publication Date
ITMI20001984A0 true ITMI20001984A0 (it) 2000-09-12
ITMI20001984A1 ITMI20001984A1 (it) 2002-03-12
IT1318689B1 IT1318689B1 (it) 2003-08-27

Family

ID=11445780

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2000MI001984A IT1318689B1 (it) 2000-09-12 2000-09-12 Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla

Country Status (23)

Country Link
US (1) US20040014693A1 (it)
EP (1) EP1318817A1 (it)
JP (1) JP2004508406A (it)
KR (1) KR20030045066A (it)
CN (1) CN1466458A (it)
AR (1) AR030635A1 (it)
AU (1) AU2002214974A1 (it)
BR (1) BR0113844A (it)
CA (1) CA2421920A1 (it)
CZ (1) CZ2003957A3 (it)
EA (1) EA200300368A1 (it)
EE (1) EE200300096A (it)
HU (1) HUP0301026A2 (it)
IL (1) IL154754A0 (it)
IT (1) IT1318689B1 (it)
MX (1) MXPA03002114A (it)
NO (1) NO20031115L (it)
NZ (1) NZ524677A (it)
PE (1) PE20020432A1 (it)
PL (1) PL361844A1 (it)
SK (1) SK4562003A3 (it)
WO (1) WO2002022134A1 (it)
ZA (1) ZA200302866B (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5780446A (en) * 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
GB9921960D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and amino acids
US6436913B1 (en) * 2000-07-25 2002-08-20 Pharmacia & Upjohn Company Use of estramustine phosphate in the treatment of bone metastasis

Also Published As

Publication number Publication date
CA2421920A1 (en) 2002-03-21
SK4562003A3 (en) 2003-09-11
AR030635A1 (es) 2003-08-27
HUP0301026A2 (hu) 2003-10-28
IT1318689B1 (it) 2003-08-27
CZ2003957A3 (cs) 2003-09-17
NZ524677A (en) 2005-02-25
JP2004508406A (ja) 2004-03-18
US20040014693A1 (en) 2004-01-22
AU2002214974A1 (en) 2002-03-26
IL154754A0 (en) 2003-10-31
EE200300096A (et) 2005-02-15
ZA200302866B (en) 2004-04-28
PL361844A1 (en) 2004-10-04
CN1466458A (zh) 2004-01-07
ITMI20001984A1 (it) 2002-03-12
WO2002022134A8 (en) 2004-03-04
WO2002022134A1 (en) 2002-03-21
EA200300368A1 (ru) 2003-08-28
EP1318817A1 (en) 2003-06-18
PE20020432A1 (es) 2002-05-11
BR0113844A (pt) 2003-06-03
NO20031115D0 (no) 2003-03-11
MXPA03002114A (es) 2003-06-19
KR20030045066A (ko) 2003-06-09
NO20031115L (no) 2003-03-11

Similar Documents

Publication Publication Date Title
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
EE200100568A (et) 6-alkenüül-, 6-alkünüül- ja 6-epoksüepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
IL150628A0 (en) Use of lipid conjugates in the treatment of disease
AU3104301A (en) Compositions and methods to effect the release profile in the transdermal administration of active agents
DE60235719D1 (de) Frauenhygieneartikel zur verabreichung von arzneimittel
HK1058041A1 (en) Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease
EE05067B1 (et) Aminoproplfosfiinhapped ning nende kasutamine meditsiinis
ATE298571T1 (de) Flüssige pharmazeutische formulierungen mit verbesserter oraler veträglichkeit
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
EE05109B1 (et) Sulfoonamiidi derivaadid, nende kasutamine meditsiinis ning meetod nende valmistamiseks
EE04344B1 (et) Telmisartaani polümorfid, meetodid nende valmistamiseks ja nende kasutamine ravimi valmistamiseks
FR2823672B1 (fr) Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
EE200200493A (et) Lipiidne kandesüsteem, selle kasutamine ravimpreparaatide valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
ITMI922779A0 (it) Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche
FR2845991B1 (fr) Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine
ITMI20001984A0 (it) Uso dell'arginina nella preparazione di un medicamento per la preparazione e trattamento degli effetti collaterali associati alla somministr
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
FR2826261B1 (fr) Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche
EE200200440A (et) Estramustiinfosfaadi või selle metaboliidi kasutamine taksaani toimimisvõimet suurendava ravimi valmistamiseks, toimeaine ning seda sisaldav kombineeritud preparaat
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
FR2864090B1 (fr) Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono